Clinical Trial Update: Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial evaluated denosumab to prevent high-turnover bone loss after bariatric surgery; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Bariatric Surgery Candidate, Bone Loss | Phase 4 | Status: COMPLETED | Results posted: 2025-10-29